{"id":"NCT01431287","sponsor":"Boehringer Ingelheim","briefTitle":"Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)","officialTitle":"A Randomised, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5 µg / 5 µg; 5 µg / 5 µg) (Delivered by the Respimat® Inhaler) Compared With the Individual Components (2.5 µg and 5 µg Tiotropium, 5 µg Olodaterol) (Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD) [TOnado TM 2]","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09","primaryCompletion":"2013-11","completion":"2013-11","firstPosted":"2011-09-09","resultsPosted":"2015-07-16","lastUpdate":"2015-07-16"},"enrollment":2539,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"tiotropium + olodaterol","otherNames":[]},{"type":"DRUG","name":"tiotropium + olodaterol","otherNames":[]},{"type":"DRUG","name":"tiotropium","otherNames":[]},{"type":"DRUG","name":"tiotropium","otherNames":[]},{"type":"DRUG","name":"olodaterol","otherNames":[]},{"type":"DEVICE","name":"Respimat","otherNames":[]}],"arms":[{"label":"tiotropium+olodaterol high dose FDC","type":"EXPERIMENTAL"},{"label":"tiotropium+olodaterol low dose FDC","type":"EXPERIMENTAL"},{"label":"olodaterol","type":"ACTIVE_COMPARATOR"},{"label":"tiotropium low dose","type":"ACTIVE_COMPARATOR"},{"label":"tiotropium high dose","type":"ACTIVE_COMPARATOR"}],"summary":"The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components (tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patients with COPD.","primaryOutcome":{"measure":"Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3h) Response on Day 169","timeFrame":"1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 169","effectByArm":[{"arm":"Olodaterol (5 μg)","deltaMin":0.136,"sd":0.009},{"arm":"Tiotropium (2.5 μg)","deltaMin":0.125,"sd":0.009},{"arm":"Tiotropium (5 μg)","deltaMin":0.165,"sd":0.009},{"arm":"Tio+Olo FDC (2.5/5 μg)","deltaMin":0.256,"sd":0.009},{"arm":"Tio+Olo FDC (5/5 μg)","deltaMin":0.268,"sd":0.009}],"pValues":[{"comp":"OG000 vs OG004","p":"<0.0001"},{"comp":"OG002 vs OG004","p":"<0.0001"},{"comp":"OG000 vs OG003","p":"< 0.0001"},{"comp":"OG001 vs OG003","p":"<0.0001"},{"comp":"OG002 vs OG003","p":"<0.0001"},{"comp":"OG003 vs OG004","p":"0.3394"},{"comp":"OG001 vs OG004","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"0.0173"},{"comp":"OG000 vs OG001","p":"0.4210"},{"comp":"OG001 vs OG002","p":"0.0014"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":240,"countries":["United States","Austria","Belgium","Brazil","Canada","China","Colombia","Croatia","Germany","Hungary","India","Ireland","Japan","Norway","Romania","Russia","Serbia","Slovakia","South Africa","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["33175291","32943047","32848380","32848379","32776202","32671684","32462607","30261995","29355547","27993292","26112656","25573406"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":106,"n":510},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Upper respiratory tract infection","Cough","Dyspnoea"]}}